Phaseline

Targets › SIRPA

SIRPA (Tyrosine-protein phosphatase non-receptor type substrate 1): drug programs, companies and trials

6 programs from 5 companies in 11 trials: 10 Phase 1, 1 Phase 2; Oncology, Hematology; next expected readout Dec 2026.

Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. (UniProt, P78324)

Open in Phaseline: the race on SIRPA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Electra TherapeuticsELA026
SIRP-directed monoclonal antibody
SIRPAPhase 2Secondary Hemophagocytic Lymphohistiocytosis (sHLH); T Cell MalignanciesMar 2028
ByondisRituximab (BYON4228)
B-lymphocyte antigen CD20 binding agent
MS4A1, SIRPAPhase 1Lymphoma; Solid TumorDec 2026
FBD BiologicsHCB301
Engineered SIRPα fused to anti-PD-L1 and TGF-β fusion protein
SIRPA, PDCD1LG2, TGFB1Phase 1Advanced Solid TumorDec 2026
SairopaADU-1805
anti-SIRPα monoclonal antibody
SIRPAPhase 1Solid Tumor, AdultMay 2027
FBD BiologicsHCB101
SIRPα-Fc fusion protein targeting CD47
SIRPA, CD47Phase 1Advanced Solid Tumor; Solid Cancer; CRC; HNSCCMay 2027
Kahr MedicalDSP107
SIRPα-4-1BBL bi-functional fusion protein; engages SIRPα on macrophages (CD172a) to block
SIRPA, TNFPhase 1Advanced Solid Tumor–

Conditions

Advanced Solid Tumor (3) Solid Tumor, Adult (1) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) (1) T Cell Malignancies (1) Solid Cancer (1) CRC (1) HNSCC (1) Lymphoma (1) Solid Tumor (1)

Modalities

mixed (3), small molecule (2), antibody (1)

Companies

FBD Biologics (2) Sairopa (1) Electra Therapeutics (1) Kahr Medical (1) Byondis (1)

Related targets

PDCD1LG2 (1) TGFB1 (1) TNF (1) CD47 (1) MS4A1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.